Inactive Instrument

Vitro Diagnostics, Inc.

VODG

US9285013036

Vitro Biopharma Inc. announced a financing transaction

October 15, 2021

Vitro Biopharma Inc. announced that it will receive $10,000,000 in funding on October 15, 2021. The company will issue non-convertible debt in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Vitro Diagnostics, Inc.

Vitro Biopharma, Inc. announced that it has received $0.175 million in funding	11/04	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	14/03	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	30/01	CI
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes	23/01	CI
Vitro Biopharma, Inc. announced that it has received $1 million in funding	10/01	CI
Vitro Biopharma, Inc. announced a financing transaction	16/11	CI
Vitro Biopharma, Inc. announced that it expects to receive $2 million in funding	16/11	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	29/23/29	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	13/23/13	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	14/23/14	CI
Vitro Biopharma, Inc. announced that it has received $0.325 million in funding	13/23/13	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	05/23/05	CI
Vitro Biopharma, Inc. announced that it has received $0.2 million in funding	14/23/14	CI
Vitro Biopharma, Inc. announced that it expects to receive CAD 0.2376 million in funding	15/23/15	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	15/23/15	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	15/23/15	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	31/23/31	CI
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	30/23/30	CI
Vitro Biopharma, Inc. amended terms of the transaction	23/23/23	CI
Vitro Biopharma, Inc. announced a financing transaction	06/23/06	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	04/22/04	CI
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million.	09/22/09	CI
Vitro Biopharma Inc. Auditor Raises 'Going Concern' Doubt	09/22/09	CI
Vitro Biopharma Inc. announced a financing transaction	15/21/15	CI
Vitro Biopharma Inc. acquired INFINIVIVE MD STEM CELL TECHNOLOGIES for $5.8 million.	31/21/31	CI

Chart Vitro Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-1.64%	90.28B
SAMSUNG BIOLOGICS CO.,LTD.	-1.97%	39.5B
BIOGEN INC.	-15.47%	31.71B
UCB	+61.28%	26.41B
BIOMARIN PHARMACEUTICAL INC.	-22.81%	14.34B
INCYTE CORPORATION	-8.82%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.77%	11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.97%	10.95B
SWEDISH ORPHAN BIOVITRUM AB	+3.30%	8.85B

Biopharmaceuticals